Indeed, axitinib, a potent tyrosine kinase inhibitor of VEGF receptors, approved for advanced renal cell carcinoma (RCC), was shown as a substrate for BCRP and MDR1 in in vivo and in vitro analyses [233]. Here, ABCG2 is linked to renal cell carcinoma.